ENFERMEDADES HEPÁTICAS
![Foto de ENFERMEDADES HEPÁTICAS](/img/grupo.png)
![Foto de Hospital Universitario de Valme](/img/noimage_org.png)
Hospital Universitario de Valme
Sevilla, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario de Valme (10)
2024
-
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Hepatology, Vol. 79, Núm. 1, pp. 135-148
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597
2022
-
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Hepatology, Vol. 76, Núm. 4, pp. 1121-1134
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
2021
-
Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD
Frontiers in Medicine, Vol. 8
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
-
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
Gut, Vol. 70, Núm. 12, pp. 2359-2372
2020
2018
-
Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts
Hepatology Communications, Vol. 2, Núm. 7, pp. 807-820
2015
-
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities
European Journal of Gastroenterology and Hepatology, Vol. 27, Núm. 1, pp. 46-54